BioGenes - antibody development with new technology platform

23-Jun-2005

BioGenes GmbH announced the successful completion of a first step of an intended technological innovation. During a comprehensive R&D process the company has significantly optimised the well-known standard mouse hybridoma technology. As a result BioGenes has now an innovative technology platform at its disposal which enables the company to produce antibodies much more efficiently and economical.

With the new platform BioGenes extends and improves its service offer especially for those customers only having a very small amount of antigen and little time for the project also. In contradiction to competitors stable clones (IgG) will be available within 3-4 months. The delivery of all positive stable clones to their customers has been a long-time company standard just like the fact that all project results as well as clones are of course their customer's property. The company now focuses on the further perfection of the technology. In consequence they will be in the position to provide their customers once more with enhanced first-class services.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances